Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Fisher

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Rheumatology (Oxford, England)|October 24, 2025
Hormonal risk factors and androgen and glucocorticoid dysregulation in Sjogren's disease and non-Sjogren's siccaJason D Turner, Jessica Tsapparelli, Lorna C Gilligan, et al.
The Lancet. Rheumatology|June 28, 2024
Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trialClaudia Worth, M Hussein Al-Mossawi, Joanne Macdonald, et al.
Nature Metabolism|August 4, 2025
Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolutionMichelangelo Certo, Elena Pontarini, Sebastian G Gilbert, et al.
Annals of the Rheumatic Diseases|March 7, 2013
Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritisAnne-Marie Quirke, Elena Birgitta Lugli, Natalia Wegner, et al.
Rheumatology (Oxford, England)|July 6, 2019
CXCL13 as biomarker for histological involvement in Sjögren's syndromeSerena Colafrancesco, Roberta Priori, Charlotte G Smith, et al.
Lancet (London, England)|December 3, 2021
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trialSimon J Bowman, Robert Fox, Thomas Dörner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 18, 2024
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging StudyThomas Dörner, Simon J Bowman, Robert Fox, et al.
Rheumatology and Therapy|February 19, 2024
Reliability Exercise of Ultrasound Salivary Glands in Sjögren's Disease: An International Web Training InitiativeBaptiste Quéré, Alain Saraux, Guillermo Carvajal-Alegria, et al.
Annals of the Rheumatic Diseases|February 14, 2018
High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control studyPaola de Pablo, Dora Romaguera, Helena L Fisk, et al.
BMC Musculoskeletal Disorders|November 6, 2015
Smoking, Porphyromonas gingivalis and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control studyBenjamin A Fisher, Alison J Cartwright, Anne-Marie Quirke, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Rheumatology (Oxford, England)|October 24, 2025
Hormonal risk factors and androgen and glucocorticoid dysregulation in Sjogren's disease and non-Sjogren's siccaJason D Turner, Jessica Tsapparelli, Lorna C Gilligan, et al.
The Lancet. Rheumatology|June 28, 2024
Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trialClaudia Worth, M Hussein Al-Mossawi, Joanne Macdonald, et al.
Nature Metabolism|August 4, 2025
Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolutionMichelangelo Certo, Elena Pontarini, Sebastian G Gilbert, et al.
Annals of the Rheumatic Diseases|March 7, 2013
Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritisAnne-Marie Quirke, Elena Birgitta Lugli, Natalia Wegner, et al.
Rheumatology (Oxford, England)|July 6, 2019
CXCL13 as biomarker for histological involvement in Sjögren's syndromeSerena Colafrancesco, Roberta Priori, Charlotte G Smith, et al.
Lancet (London, England)|December 3, 2021
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trialSimon J Bowman, Robert Fox, Thomas Dörner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 18, 2024
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging StudyThomas Dörner, Simon J Bowman, Robert Fox, et al.
Rheumatology and Therapy|February 19, 2024
Reliability Exercise of Ultrasound Salivary Glands in Sjögren's Disease: An International Web Training InitiativeBaptiste Quéré, Alain Saraux, Guillermo Carvajal-Alegria, et al.
Annals of the Rheumatic Diseases|February 14, 2018
High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control studyPaola de Pablo, Dora Romaguera, Helena L Fisk, et al.
BMC Musculoskeletal Disorders|November 6, 2015
Smoking, Porphyromonas gingivalis and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control studyBenjamin A Fisher, Alison J Cartwright, Anne-Marie Quirke, et al.
Pageof 9